3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow ceftolozane: new trials by email Literature Review of ceftolozane trials Research Report on ceftolozane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Cefepime, Ceftolozane, Laboratory Biomarker Analysis - Other Infectious Diseases | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2018-05-16 | 2022-03-15 |
| Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo - Complicated Intra-abdominal Infection | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 122 | 2010-06-25 | 2018-10-25 |
| Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections CXA-101, Ceftazidime - Complicated Urinary Tract Infection | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 129 | 2009-06-30 | 2018-10-18 |
Pyelonephritis (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · M.D. Anderson Cancer Center (1)
United States (3) · Argentina (1) · Georgia (1) · Germany (1) · Poland (1) · Russia (1) · Serbia (1)
Ahmad Haidar, MD (1) · Florian Wagenlehner, MD (1) · Ian Friedland, MD (1) · Issam I Raad (1) · Ryszard Gellert, MD (1)